Matches in SemOpenAlex for { <https://semopenalex.org/work/W4313440119> ?p ?o ?g. }
Showing items 1 to 84 of
84
with 100 items per page.
- W4313440119 endingPage "33" @default.
- W4313440119 startingPage "27" @default.
- W4313440119 abstract "Abstract The objective of this study was to examine the effect of ketoprofen with or without combination with xylazine on the level of cyclooxygenase-2 in mice. The intraperitoneal (i.p.) dose of ketoprofen and xylazine that caused an analgesic response in half of the mouse population was 1.26 mg/kg and 6.63 mg/kg, respectively. Serum cyclooxygenase-2 concentration (activity) in the control mice was 16.94 ng/ml. The ketoprofen-treated group (2.52 mg/kg, i.p.) decreased the cyclooxygenase-2 concentration by 58% (7.16 ng/ml). The combined ketoprofen and xylazine treatment (13.26 mg/kg, i.p.) decreased the cyclooxygenase-2 by 94% (0.98 ng/ml). The ketoprofen plasma concentration in the combined treatment group was significantly higher compared to the ketoprofen treatment group. Ketoprofen plasma concentrations measured at 0.25, 0.5, 1, 2, 4, and 24 hours were 19.07, 18.94, 14.66, 6.53, 5.44, and 5.54 µg/ml, respectively. Plasma concentrations of ketoprofen and xylazine were raised to 28.74, 29.74, 15.32, 13.04, 14.64, and 11.95 µg/ml or by 51%, 56%, 5%, 100%, 169%, and 116%, respectively. Ketoprofen pharmacokinetic variables were increased (AUC 0-∞ (515%), AUMC 0-∞ (2389%), MRT (305%), t 1/2β (375%), T max (100%), and C max (55%)), while other values were decreased (K el (79%), V ss (25%), and Cl (88%)). Our findings suggested a synergistic interaction between ketoprofen and xylazine on the level of cyclooxygenase-2 (pharmacodynamic interaction) which was exerted by modification of the ketoprofen pharmacokinetic properties in mice." @default.
- W4313440119 created "2023-01-06" @default.
- W4313440119 creator A5036558738 @default.
- W4313440119 creator A5047095675 @default.
- W4313440119 creator A5058380064 @default.
- W4313440119 date "2022-12-31" @default.
- W4313440119 modified "2023-09-27" @default.
- W4313440119 title "Pharmacokinetic Criteria of Ketoprofen and its Cyclooxygenase-2 Inhibition in Mice: Influence of Xylazine Administration" @default.
- W4313440119 cites W17682570 @default.
- W4313440119 cites W1964137480 @default.
- W4313440119 cites W1964714442 @default.
- W4313440119 cites W1975403685 @default.
- W4313440119 cites W1977467773 @default.
- W4313440119 cites W1994684867 @default.
- W4313440119 cites W2026374776 @default.
- W4313440119 cites W2028276188 @default.
- W4313440119 cites W2063909696 @default.
- W4313440119 cites W2091027075 @default.
- W4313440119 cites W2103351070 @default.
- W4313440119 cites W2133756704 @default.
- W4313440119 cites W2335373361 @default.
- W4313440119 cites W2906488195 @default.
- W4313440119 cites W3021031602 @default.
- W4313440119 cites W3155644271 @default.
- W4313440119 cites W3179927784 @default.
- W4313440119 cites W3197177002 @default.
- W4313440119 cites W4233921710 @default.
- W4313440119 cites W4312926236 @default.
- W4313440119 doi "https://doi.org/10.2478/macvetrev-2022-0031" @default.
- W4313440119 hasPublicationYear "2022" @default.
- W4313440119 type Work @default.
- W4313440119 citedByCount "1" @default.
- W4313440119 countsByYear W43134401192023 @default.
- W4313440119 crossrefType "journal-article" @default.
- W4313440119 hasAuthorship W4313440119A5036558738 @default.
- W4313440119 hasAuthorship W4313440119A5047095675 @default.
- W4313440119 hasAuthorship W4313440119A5058380064 @default.
- W4313440119 hasBestOaLocation W43134401191 @default.
- W4313440119 hasConcept C111113717 @default.
- W4313440119 hasConcept C112705442 @default.
- W4313440119 hasConcept C181199279 @default.
- W4313440119 hasConcept C185592680 @default.
- W4313440119 hasConcept C2779591255 @default.
- W4313440119 hasConcept C2779689624 @default.
- W4313440119 hasConcept C2780744026 @default.
- W4313440119 hasConcept C2780795376 @default.
- W4313440119 hasConcept C2780820201 @default.
- W4313440119 hasConcept C42219234 @default.
- W4313440119 hasConcept C55493867 @default.
- W4313440119 hasConcept C71924100 @default.
- W4313440119 hasConcept C98274493 @default.
- W4313440119 hasConceptScore W4313440119C111113717 @default.
- W4313440119 hasConceptScore W4313440119C112705442 @default.
- W4313440119 hasConceptScore W4313440119C181199279 @default.
- W4313440119 hasConceptScore W4313440119C185592680 @default.
- W4313440119 hasConceptScore W4313440119C2779591255 @default.
- W4313440119 hasConceptScore W4313440119C2779689624 @default.
- W4313440119 hasConceptScore W4313440119C2780744026 @default.
- W4313440119 hasConceptScore W4313440119C2780795376 @default.
- W4313440119 hasConceptScore W4313440119C2780820201 @default.
- W4313440119 hasConceptScore W4313440119C42219234 @default.
- W4313440119 hasConceptScore W4313440119C55493867 @default.
- W4313440119 hasConceptScore W4313440119C71924100 @default.
- W4313440119 hasConceptScore W4313440119C98274493 @default.
- W4313440119 hasIssue "1" @default.
- W4313440119 hasLocation W43134401191 @default.
- W4313440119 hasOpenAccess W4313440119 @default.
- W4313440119 hasPrimaryLocation W43134401191 @default.
- W4313440119 hasRelatedWork W2008001785 @default.
- W4313440119 hasRelatedWork W2010116591 @default.
- W4313440119 hasRelatedWork W2032043921 @default.
- W4313440119 hasRelatedWork W2077832397 @default.
- W4313440119 hasRelatedWork W2119659415 @default.
- W4313440119 hasRelatedWork W2227061539 @default.
- W4313440119 hasRelatedWork W2409440602 @default.
- W4313440119 hasRelatedWork W2594910449 @default.
- W4313440119 hasRelatedWork W2992709639 @default.
- W4313440119 hasRelatedWork W4313440119 @default.
- W4313440119 hasVolume "46" @default.
- W4313440119 isParatext "false" @default.
- W4313440119 isRetracted "false" @default.
- W4313440119 workType "article" @default.